DACLATASVIR dihydrochl. eq.60mg base/ SOFOSBUVIR 400mg, tab.


Valid Article - Pangenotypic direct-acting antiviral combinations
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list


Add Kit To Wishlist



Therapeutic Action

Fixed dose combination of a NS5A inhibitor (daclatasvir) and a nucleotide analogue NS5B polymerase inhibitor (sofosbuvir)


Chronic hepatitis C virus (HCV)

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Tablets have a bitter taste, they should be swallowed whole (not crushed or chewed), with meals.

The FDC replaces the single tablets of 60 mg daclastavir and 400 mg sofosbuvir.

To be used in combination with or without ribavirin.


Below 25ºC